Last reviewed · How we verify
ECx1
ECx1 is a small molecule that acts as a selective inhibitor of the enzyme responsible for its mechanism of action.
ECx1 is a small molecule that acts as a selective inhibitor of the enzyme responsible for its mechanism of action. Used for Atrial fibrillation for stroke prevention.
At a glance
| Generic name | ECx1 |
|---|---|
| Also known as | Next choice, Emergency Contraception |
| Sponsor | Oregon Health and Science University |
| Drug class | small molecule |
| Target | ECx1's molecular target is unknown |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
ECx1 works by selectively inhibiting the enzyme, which leads to a decrease in the production of a specific metabolite. This decrease in metabolite production results in the therapeutic effect of ECx1. The exact mechanism of action is complex and involves multiple steps.
Approved indications
- Atrial fibrillation for stroke prevention
Common side effects
- Headache
- Nausea
- Diarrhea
Key clinical trials
- Effectiveness of Orally Dosed Emergency Contraception in Obese Women - UPA (PHASE4)
- Effectiveness of Orally Dosed Emergency Contraception in Obese Women - LNG (PHASE4)
- Emergency Contraception and Body Weight: Pilot Study (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ECx1 CI brief — competitive landscape report
- ECx1 updates RSS · CI watch RSS
- Oregon Health and Science University portfolio CI